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asthmatic patients and its relation to disease severity.
Methods: This case control study was carried out on 70 individuals classified into 20 healthy con-
trol subjects and 50 asthmatic patients that were admitted in Chest Department, Benha university
hospital in the period between March 2013 and December 2014. Asthma diagnosis (history and
PFT) and assessment of its severity were conducted according to the guidelines of Global Initiative
for Asthma (GINA, 2011). Eosinophil percentage in the sputum of asthmatic patients was done.
Measurement of stem cell factor (SCF) in the sera was done by Enzyme-Linked Immunosorbent
Assay.
Results: Our results found a statistically significant difference (P value < 0.001) between asthmatic
patients and control subjects in the mean values of SCF (1192.34 ± 789.89 versus 326.29 ± 274.38
respectively). There was a statistically significant difference (P value = 0.001) between eosinophilic
and non eosinophilic phenotype (1457.77 ± 648.83 versus 130.59 ± 83.27 respectively). There was
a statistically significant difference in the level of SCF among different degrees of asthma severity
(P= 0.001). Also, there was a significant negative correlation (r= 0.288) between SCF levels and
FEV1% and significant positive correlation between SCF levels and sputum (r= 0.712) and blood
(r= 0.548) eosinophils% in asthmatic patients.
Conclusion: This study demonstrated that the serum level of SCF was higher in asthmatic patients
especially among eosinophilic phenotype than among healthy control subjects. Also there was a sig-
nificant association between higher SCF and higher levels of asthma severity, sputum and blood
eosinophil%.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bronchial asthma is a common chronic disease of the respira-
tory system that affects approximately 300 million people
worldwide. It is a heterogeneous disease, usually characterized
by chronic airway inflammation. It is defined by the history of
respiratory symptoms such as wheeze, shortness of breath,
chest tightness and cough that vary over time and in intensity,
together with variable expiratory airflow limitation [1]. Stem
cell factor (SCF) is a dimeric molecule that exerts its biological
functions by binding to and activating the receptor tyrosine
kinase c-Kit. Activation of c-Kit leads to its autophosphoryla-tion and initiation of signal transduction. Activation of c-Kit
signaling has been found to mediate cell survival, migration,
and proliferation depending on the cell type. Signaling from
c-Kit is crucial for normal hematopoiesis, pigmentation, fertil-
ity, gut movement, and some aspects of the nervous system.
Deregulated c-Kit kinase activity has been found in a number
of pathological conditions, including cancer and allergy [2].
SCF can exist both as a transmembrane and a soluble protein.
The soluble form of SCF contains a proteolytic cleavage site in
exon 6. Cleavage at this site allows the extracellular portion of
the protein to be released. The transmembrane form of SCF is
formed by alternative splicing that excludes exon 6. Both
forms of SCF bind to c-Kit and are biologically active [3].
Although SCF was initially described as a mast cell growth
factor; it appeared to be a pleiotropic cytokine exerting its roleuberculosis.
2 Editorialat the first stages of bone marrow stem cell development,
inducing eosinophil activation and basophil chemotaxis and
survival [4]. SCF appears to play a significant role in eosino-
phil associated inflammation in allergic airway inflammation.
SCF can play an important role in eosinophil activation,
inducing degranulation, leukotriene, and chemokine produc-
tion [5].
Aim of the work
This study was carried out to assess serum level of stem cell
factor in asthmatic patients and to evaluate its relation to dis-
ease severity.
Subjects and method
This case control study was carried out on 70 individuals, 20
healthy control subjects and 50 asthmatic patients that were
admitted in Chest Department, Benha University hospital
in the period between March 2013 and December 2014. Sub-
jects were divided into 2 groups: Group I: 50 patients with
bronchial asthma and Group II: 20 apparently healthy indi-
viduals as a control group. Group I was further divided
according to severity of asthma into: group Ia; mild persis-
tent, group Ib; moderate persistent and group Ic; severe per-
sistent asthma [6]. Group I was further divided into
eosinophilic and non eosinophilic asthma according to per-
cent of sputum eosinophil [7].
Inclusion criteria for group I
 Stable asthmatic patients with airway obstruction (FEV1/
FVC< 70%) and with degree of reversibility in FEV1 of
P12% or 200 ml from pre bronchodilator value [6].
 Stopping corticosteroids 12 h before laboratory tests for
severe persistent asthmatic patients.
Exclusion criteria
 Patients receiving high dose systemic corticosteroid (pred-
nisone 1 mg/kg/day).
 Patients known to have systemic inflammatory diseases.
All subjects were subjected to the following:
I. Thorough history taking and clinical examination.
II. Plain chest X-ray (P-A view).
III. Pulmonary function test (spirometry pre and post bron-
chodilator) [8].
IV. Laboratory investigations:
1. Complete blood count.
2. Erythrocyte sedimentation rate.
3. Liver functions tests.
4. Kidney function tests.
5. Eosinophil percentage in the sputum of asthmatic
patients. All patients gave sufficient sputum samples
with no need for induced sputum technique. Sputumwas treated by adding equivolume N-acetylcysteine,
then it was spread on a slide then fixed with methanol
10%, the slide was stained with Leishman stain, then
eosinophil percentage in the sample was calculated [9].
6. Measurement of serum level of stem cell factor by
Enzyme-Linked Immunosorbent Assay (ELISA).
Principle of the Assay
SCF in standards and samples was sandwiched by the immo-
bilized antibody and the biotinylated polyclonal antibody
specific for SCF, which was recognized by a streptavidin–per-
oxidase conjugate. All unbound material was then washed
away and a peroxidase enzyme substrate was added. The color
development was stopped and the intensity of the color was
measured [10].
Statistics
The data were entered into a personal computer. The statistics
were performed using SPSS statistical program (version 20).Results
Among the patients group, there were 43 (86%) females and 7
(14%) males. The ages of the patients ranged between 25 and
67 years (mean = 47.04 ± 12.08) and their BMI ranged from
19.53 to 47.61 kg/m2. Among the control group, there were
15 (75%) females and 5 (25%) males. Their ages ranged
between 36 and 68 years (mean = 45.15 ± 7.58). The patients
and control groups were matched for sex, age and BMI
(P> 0.05) (Table 1). Out of 50 asthmatic patients, 2 (4%)
patients were mild persistent, 19 (38%) patients were moderate
persistent and 29 (58%) patients were severely persistent
(Table 2). And among asthma phenotype, 40 (80%) patients
were eosinophilic and 10 (20%) patients were non eosinophilic
(Table 3). There was a statistically significant difference
(P value < 0.05) in the mean value of eosinophil percentage
in sputum among asthma severity as it was higher among
patients with severe asthma compared with the mild and mod-
erate persistent. While percent of eosinophil in blood increased
with increasing asthma severity with no statistically significant
difference (Table 4). There was a highly statistical significant
difference in the mean level of SCF between case and control
group (1192.34 ± 789.89 versus 326.29 ± 274.38 respectively)
(Table 5). There was a highly statistical significant difference in
the level of SCF among different degrees of severity in asth-
matic group as it was significant higher in severe persistent
asthmatics compared with mild and moderate persistent
(Table 6). There was a statistically significant difference in
the level of SCF between eosinophilic and non-eosinophilic
asthma (1457.77 ± 648.83 versus 130.59 ± 83.27 respectively)
(Table 7). A significant positive correlation was found between
SCF and eosinophil percent in sputum (r= 0.71) (Table 8 and
Fig. 1) and blood (r= 0.55) (Table 8 and Fig. 2) as well as age
(r= 0.37) (Table 8), also there was a significant negative
correlation between SCF level and FEV1% predicted of
asthmatic patients (r= 0.29) (Table 8 and Fig. 3).
Table 1 Demographic data and pulmonary function (spirometry) of studied groups.
Cases Control P value
No. 50 20
Age (years) 47.04 ± 12.08 45.15 ± 7.58 >0.05
Females no. 43 (86%) 15 (75%) >0.05
Males no. 7 (14%) 5 (25%)
BMI (kg/m2) 30.38 ± 6.19 29.34 ± 3.13 >0.05
FVC (% pred.) 52.6 ± 17.65 88.45 ± 5.53 .000
FEV1 (% pred.) 63.64 ± 19.4 86.45 ± 5.59 .000
PEF (% pred.) 51.42 ± 19.62 82.7 ± 9.65 .000
Table 2 Classification of asthmatic patients according to
severity.
Severity Case 50 (100%)
No %
Mild persistent 2 4
Moderate persistent 19 38
Severe persistent 29 58
Table 3 Classification of asthmatic patients according to
phenotype.
Asthma phenotype Case 50 (100%)
No %
Eosinophilic 40 80
Non eosinophilic 10 20
Editorial 3Discussion
The results of this study revealed that there was a statistically
significant difference between asthmatic patients and control
subjects in the mean values of SCF (1192.34 ± 789.89 versus
326.29 ± 274.38 respectively). In addition there was a signifi-
cant difference in the level of SCF among severity groups in
asthmatic patients. Lei et al., had measured the serum concen-
trations of SCF and IL-31 in allergic asthmatic patients, which
were significantly higher than those in normal control subjects
[11]. This result was also in agreement with Makowska et al.,
who found that mean serum SCF level in the group of
asthmatics was significantly higher as compared to healthy
controls. The level of SCF was higher in patients with severe
asthma as compared to patients with non-severe asthma [4].
Abd El Halim et al., assessed the level of SCF in peripheral
blood in patients with asthma and its correlation with asthmaTable 4 Mean sputum and blood eosinophil among asthmatic pati
Mild persistent Moderate
Range Mean ± SD Range
%Sputum eosinophil 4–6 5 ± 1.41 0–10
%Blood eosinophil 1.3–6 3.65 ± 3.32 1–8.6severity and they found that there was a statistically significant
difference (P value < 0.01) between asthmatic patients and
control subjects in the mean values of SCF (1528.93 ±
465.40 versus 760.60 ± 427.62 respectively). Also there was a
statistically significant correlation between severity of asthma
and SCF levels (r= 0.526) [12]. Also, Safwat et al., found that
mean serum SCF level in the group of asthmatics (n= 29) was
significantly higher as compared to healthy controls and the
level of SCF was higher in patients with severe asthma as
compared to patients with non-severe asthma [13]. Other stud-
ies done by Kanabe et al., and Kim et al., showed increased
production of SCF in different allergic diseases like asthma,
allergic rhinitis and atopic dermatitis [14,15]. High level of
SCF in bronchial asthma could be explained by Ashman
(1999) who illustrated that SCF is a known inducer of mast cell
proliferation and mast cell degranulation [16]. In previous
studies done by Oliveira et al., they have identified that SCF
production during allergic inflammation can contribute signif-
icantly to the induction of the eosinophilic inflammatory
responses and the airway hyperreactivity via direct mast cell
activation [5]. Also, Da Silva and Frossard, illustrated that
stem cell factor (SCF) is a major mast cell growth factor, which
could be involved in the local increase of mast cell number in
the asthmatic airways. So, SCF expression increases in asth-
matic patients [17]. Guntur and Reinero, had illustrated that
stem cell factor (SCF), the ligand for c-Kit, is an important
growth factor and activator of mast cells and eosinophils
and that serum and airway SCF concentrations have been
shown to correlate with asthma severity [18]. Our study
showed that SCF was higher in eosinophilic asthma compared
to non eosinophilic asthma (non eosinophilic asthma was
defined according to Tsoumakidou et al., by presence of less
than 2% eosinophil in sputum) [7]. This result can be explained
by Hartman et al., who demonstrated that human peripheral
blood eosinophils are a source of SCF and that result might
contribute to a better understanding of the interactions
between eosinophils and mast cells in allergic inflammation
[19]. In a study made by Oliveira et al., they demonstrated that
eosinophils have significant levels of surface c-Kit protein and
SCF receptor. Also they demonstrated that SCF-activatedents.
persistent Severe persistent P value
Mean ± SD Range Mean ± SD
5.47 ± 2.89 0–36 11.86 ± 8.91 60.05
3.99 ± 2.08 1–18.6 5.49 ± 4.23 >0.05
Table 5 SCF (pg/ml) among case and control groups.
Case Control P value of T-test
Range 57–3219.6 68.7–1328.5 .000
Mean ± SD 1192.34 ± 789.89 326.29 ± 274.38
Table 6 SCF value among different degrees of severity in asthmatic group.
Severity P value of F-test
SCF Mild Moderate Severe .001
R Mean ± SD Range Mean ± SD Range Mean ± SD
428 to 483 455.5±38.89 82.3 to 1251.8 877.58 ±330.02 57–3219.6 1449.37 ±920.52
Table 7 Comparison between different asthma phenotypes regarding SCF.
Non eosinophilic Eosinophilic P value of T-test
Range 57–328.2 428–3219.6 .001
Mean ± SD 130.59 ± 83.27 1457.77 ± 648.83
Table 8 Correlation between SCF values and different patients parameters.
SCF
Age Pearson correlation 0.369
Sig. 0.008
%Eosinophil in sputum Pearson correlation 0.712
Sig. 0.000
%Eosinophil in blood Pearson correlation 0.548
Sig. 0.000
FEV1% pred. Pearson correlation 0.288
Sig. 0.04
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Figure 1 Correlation between SCF and eosinophil% in sputum.
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Figure 2 Correlation between SCF and eosinophil% in blood.
4 Editorialeosinophils degranulate and release eosinophil peroxidase and
leukotriene C4 in a dose-dependent manner [5]. Also Munitz
and Levi-Schaffer, demonstrated that eosinophils synthesize,
store, and release SCF [20]. The current study showed signifi-
cant positive correlation between SCF levels and sputum
(r= 0.712) and blood (r= 0.548) eosinophils% among asth-
matic patients, higher sputum and blood eosinophils% were
associated with higher SCF levels and vice versa, and a statis-
tical significant negative correlation (r= 0.288) betweenSCF value and FEV1% predicted among asthmatic patients,
lower FEV1% was associated with higher SCF levels and vice
versa. These results also were in agreement with Abd El Halim
et al., in which a statistically significant negative correlation
(r= 0.456) was present between SCF levels and FEV1%
among asthmatic patients. In addition, there was a significant
positive correlation between SCF levels and blood (r= 0.598)
and sputum (r= 0.688) eosinophils% in asthmatic patients
[11]. Makowska et al., found that the level of SCF was higher
in the group of patients with severe asthma as compared to
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Figure 3 Correlation between SCF and FEV1% pred.
Editorial 5patients with non-severe asthma (1054 ± 41 pg/ml versus
819 ± 50 pg/ml; P< 0.01) [4].
In conclusion, this work demonstrated that serum level of
SCF was higher among asthmatic patients than among healthy
control subjects. Additionally, there was a statistically signifi-
cant association between higher SCF levels and higher levels
of severity of bronchial asthma and blood and sputum eosino-
phils percentage. Also SCF was higher among eosinophilic
phenotype. These results suggest a role for SCF in asthmatic
inflammation.
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